# US 2024/0005439 A1 · Imaging methods and radiotracers for use therein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0005439 A1
- Document ID: US20240005439A1
- Status: Published application
- Kind: A1
- Application number: 18/255,557
- Filed: 2021-12-02
- Published: 2024-01-04
- Earliest claimed: 2020-12-02
- Applicants: Vestlandets Innovasjonsselskap AS (Vis)
- Inventors: Olav TENSTAD; Tom Christian Holm ADAMSEN
- Web page: https://patentgrep.com/patent/US20240005439A1

## CPC

- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of imaging a subject, the method comprising the steps: administering a radiotracer to the subject such that the radiotracer enters the bloodstream of the subject; allowing the radiotracer to accumulate in a kidney of the subject; and imaging said kidney using positron emission tomography (PET); wherein the radiotracer comprises a protein labelled with a 6-[18F]fluoropyridin-3-ylcarboxy group. The disclosure also relates to radiotracers and compositions suitable for use in said method, as well as to processes, kits and cassettes for preparing said radiotracers.

## Claims

### Claim 1

A method of imaging a subject, the method comprising the steps:
administering a radiotracer to the subject such that the radiotracer enters the bloodstream of the subject;
allowing the radiotracer to accumulate in a kidney of the subject; and
imaging said kidney using positron emission tomography (PET);
wherein the radiotracer comprises a protein labelled with a 6-[18F]fluoropyridin-3-ylcarboxy group.

### Claim 2 (depends on 1)

The method of claim 1, wherein the 6-[18F]fluoropyridin-3-ylcarboxy group is attached to an amino group of the protein, to an N-terminal amino group of the protein, or to an amino group present on a lysine side-chain of the protein.

### Claim 3

(canceled)

### Claim 4 (depends on 2)

The method of claim 2, wherein the protein is labelled by acylating said amino group with an ester of 6-[18F]fluoronicotinic acid, or with a 6-[18F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein:
(i) the protein is freely filtered by the glomeruli and absorbed by the proximal tubular cells; and/or
(ii) the protein has a molecular weight of less than 20 kDa, e.g., less than 15 kDa; and/or
(iii) the protein is a ligand for the megalin receptor and/or the cubilin receptor; and/or
(iv) wherein the radiotracer comprises said protein in substantially monomeric form.

### Claim at position 7

7-8. (canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the protein is selected from cytochrome C, cystatin C, aprotinin, lysozyme, and fragments and variants thereof.

### Claim at position 9

10-11. (canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the radiotracer is administered by intravenous administration.

### Claim 13 (depends on 1)

The method of claim 1, wherein the method further comprises determining the glomerular filtration rate (GFR) of the subject based on the acquired PET images.

### Claim 14

A radiotracer comprising a protein labelled with a 6-[18F]fluoropyridin-3-ylcarboxy group, wherein the protein is a ligand for the megalin receptor and/or the cubilin receptor.

### Claim 15 (depends on 14)

The radiotracer of claim 14, wherein the 6-[18F]fluoropyridin-3-ylcarboxy group is attached to an amino group of the protein, to an N-terminal amino group of the protein, or to an amino group present on a lysine side-chain of the protein.

### Claim 16

(canceled)

### Claim 17 (depends on 14)

The radiotracer of claim 14, wherein the protein is labelled by acylating said amino group with an ester of 6-[18F]fluoronicotinic acid, or with a 6-[18F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester.

### Claim 18

(canceled)

### Claim 19 (depends on 14)

The radiotracer of claim 14, wherein the protein is freely filtered by the glomeruli and absorbed by the proximal tubular cells.

### Claim 20 (depends on 14)

The radiotracer of claim 14, wherein the protein is selected from cytochrome C, cystatin C, aprotinin, lysozyme, and fragments and variants thereof.

### Claim 21

(canceled)

### Claim 22 (depends on 14)

The radiotracer of claim 14, wherein the radiotracer comprises said protein in substantially monomeric form.

### Claim 23 (depends on 14)

A radiotracer composition comprising a radiotracer of claim 14 and a pharmaceutically acceptable excipient, diluent or carrier.

### Claim 24 (depends on 14)

A method of imaging a subject by positron emission tomography (PET) comprising administering a radiotracer of claim 14 to the subject.

### Claim 25

(canceled)

### Claim 26 (depends on 14)

A process for preparing the radiotracer of claim 14, the process comprising:
contacting a protein with an ester of 6-[18F]fluoronicotinic acid under conditions such that the protein undergoes a reaction with said ester, thereby labelling the protein with a 6-[18F]fluoropyridin-3-ylcarboxy group;
wherein the protein is a ligand for the megalin receptor and/or the cubilin receptor.

### Claim 27

(canceled)

### Claim 28 (depends on 26)

The process of claim 26, wherein the process is automated.

### Claim 29 (depends on 14)

A kit for preparing the radiotracer of claim 14, the kit comprising:
a first container comprising a solid support on which an ester of nicotinic acid is immobilized, wherein a leaving group is present at the 6-position of the pyridine ring of the nicotinic acid, and wherein the first container is adapted such that a solution comprising [18F]fluoride can be introduced into the container and reacted with the immobilized ester to form an ester of 6-[18F]fluoronicotinic acid; and
a second container comprising a protein, wherein the protein is a ligand for the megalin receptor and/or the cubilin receptor.

### Claim 30

A cassette suitable for use with an automated radiosynthesis apparatus, the cassette comprising:
a vessel containing an ester of nicotinic acid, wherein a leaving group is present at the 6-position of the pyridine ring of the nicotinic acid; and
a vessel containing a protein, wherein the protein is a ligand for the megalin receptor and/or the cubilin receptor.
